Global Health Developments: Deals, Dramatics, and Discoveries
Published on: May 2, 2026, 10:26 a.m. | Source: Devdiscourse
LEO Pharma plans to acquire the U.S. drug developer Replay for $50 million upfront, enhancing its offerings in dermatology with an innovative platform for rare genetic skin diseases. Bristol Myers Squibb outperformed profit expectations due to strong sales of blood thinner and cancer drugs. In other news, Cardinal Health's revenue outlook was clouded by recent legislative changes, while the Canadian health regulator approved a second generic version of Novo Nordisk’s Ozempic.
